Use of buprenorphine for those with employer-sponsored insurance during the initial phase of the COVID-19 pandemic

OBJECTIVE: To quantify weekly rates of use of buprenorphine for those with employer-based insurance and whether the rate differs based on county-level measures of race, historical fatal drug overdose rate, and COVID-19 case rate. METHODS: We used 2020 pharmaceutical claims for 4.8 million adults fro...

Descripción completa

Detalles Bibliográficos
Autores principales: Cantor, Jonathan, Dick, Andrew W., Haffajee, Rebecca, Pera, Megan F., Bravata, Dena M., Stein, Bradley D., Whaley, Christopher M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8546915/
https://www.ncbi.nlm.nih.gov/pubmed/34080552
http://dx.doi.org/10.1016/j.jsat.2021.108384

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8546915/
https://www.ncbi.nlm.nih.gov/pubmed/34080552
http://dx.doi.org/10.1016/j.jsat.2021.108384

Ejemplares similares